BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tapper EB, Aberasturi D, Zhao Z, Hsu CY, Parikh ND. Outcomes after hepatic encephalopathy in population-based cohorts of patients with cirrhosis. Aliment Pharmacol Ther 2020;51:1397-405. [PMID: 32363684 DOI: 10.1111/apt.15749] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Tapper EB. A Trial of Ornithine Phenylacetate and the Arc of Ammonia's History in the Management of Overt Hepatic Encephalopathy. Clin Gastroenterol Hepatol 2021;19:2493-5. [PMID: 33157316 DOI: 10.1016/j.cgh.2020.11.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Tapper EB, Zhao Z, Winder GS, Parikh ND. Deprescribing zolpidem reduces falls and fractures in patients with cirrhosis. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100478] [Reference Citation Analysis]
3 Bloom PP, Donlan J, Torres Soto M, Daidone M, Hohmann E, Chung RT. Fecal microbiota transplant improves cognition in hepatic encephalopathy and its effect varies by donor and recipient. Hepatol Commun 2022. [PMID: 35384391 DOI: 10.1002/hep4.1950] [Reference Citation Analysis]
4 Rahimi RS, Brown KA, Flamm SL, Brown RS Jr,. Overt Hepatic Encephalopathy: Current Pharmacologic Treatments and Improving Clinical Outcomes. Am J Med 2021:S0002-9343(21)00409-5. [PMID: 34242619 DOI: 10.1016/j.amjmed.2021.06.007] [Reference Citation Analysis]
5 Kochar B, Ufere NN, Ritchie CS, Lai JC. The 5Ms of Geriatrics in Gastroenterology: The Path to Creating Age-Friendly Care for Older Adults With Inflammatory Bowel Diseases and Cirrhosis. Clin Transl Gastroenterol 2022. [PMID: 35080513 DOI: 10.14309/ctg.0000000000000445] [Reference Citation Analysis]
6 Tapper EB, Zhao Z, Mazumder N, Parikh ND. Incidence of, Risk Factors for, and Outcomes After Ascites in a Population-Based Cohort of Older Americans. Dig Dis Sci 2022. [PMID: 35262903 DOI: 10.1007/s10620-022-07454-3] [Reference Citation Analysis]
7 Kuang Y, Wu X, Lai H, Wang Z, Lei Q, Zhong W, Yang Y, Deng C, Zhou Z. Abnormal corpus callosum induced by overt hepatic encephalopathy impairs interhemispheric functional coordination in cirrhosis patients. Ann Transl Med 2021;9:1579. [PMID: 34790785 DOI: 10.21037/atm-21-5109] [Reference Citation Analysis]
8 Bloom PP, Tapper EB. The Use of Administrative Data to Investigate the Population Burden of Hepatic Encephalopathy. J Clin Med 2020;9:E3620. [PMID: 33182743 DOI: 10.3390/jcm9113620] [Reference Citation Analysis]
9 Williams S, Louissaint J, Nikirk S, Bajaj JS, Tapper EB. Deprescribing medications that may increase the risk of hepatic encephalopathy: A qualitative study of patients with cirrhosis and their doctors. United European Gastroenterol J 2021;9:193-202. [PMID: 33226300 DOI: 10.1177/2050640620975224] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Long L, Li H, Deng G, Wang X, Lu S, Li B, Meng Z, Gao Y, Qian Z, Liu F, Lu X, Ren H, Shang J, Li H, Wang S, Zheng Y, Yan H, Yin S, Tan W, Zhang Q, Zheng X, Chen J, Luo S, Zhao J, Yuan W, Li T, Zheng R, Liu J, Liu X, Gu W, Li S, Mei X, Chen R, Huang Y. Impact of Hepatic Encephalopathy on Clinical Characteristics and Adverse Outcomes in Prospective and Multicenter Cohorts of Patients With Acute-on-Chronic Liver Diseases. Front Med (Lausanne) 2021;8:709884. [PMID: 34409052 DOI: 10.3389/fmed.2021.709884] [Reference Citation Analysis]
11 Tapper EB, Essien UR, Zhao Z, Ufere NN, Parikh ND. Racial and ethnic disparities in rifaximin use and subspecialty referrals for patients with hepatic encephalopathy in the United States. J Hepatol 2022:S0168-8278(22)00116-7. [PMID: 35367057 DOI: 10.1016/j.jhep.2022.02.010] [Reference Citation Analysis]
12 Bloom PP, Tapper EB, Young VB, Lok AS. Microbiome therapeutics for hepatic encephalopathy. J Hepatol 2021;75:1452-64. [PMID: 34453966 DOI: 10.1016/j.jhep.2021.08.004] [Reference Citation Analysis]
13 Volk ML, Burne R, Guérin A, Shi S, Joseph GJ, Heimanson Z, Ahmad M. Hospitalizations and healthcare costs associated with rifaximin versus lactulose treatment among commercially insured patients with hepatic encephalopathy in the United States. J Med Econ 2021;24:202-11. [PMID: 33464935 DOI: 10.1080/13696998.2021.1877148] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Tapper EB, Kenney B, Nikirk S, Levine DA, Waljee AK. Animal Naming Test Is Associated With Poor Patient-Reported Outcomes and Frailty in People With and Without Cirrhosis: A Prospective Cohort Study. Clin Transl Gastroenterol 2022. [PMID: 35080516 DOI: 10.14309/ctg.0000000000000447] [Reference Citation Analysis]